Therapeutic Solutions International Awarded Landmark Patent for Cancer and COVID-19 Treatment
Retrieved on:
Tuesday, December 28, 2021
Biotechnology, Infectious Diseases, Health, Pharmaceutical, Oncology, United States Patent Office fire, B cell, Cancer, FDA, Toxicity, RNA, Treatment, Severe acute respiratory syndrome coronavirus 2, Company, Immune system, Thymoquinone, Knowledge, CEO, Intrinsic and extrinsic properties, IDO, Breast cancer, Virus, Patent, University, Associated, Neoplasm, Animal, Vaccine, Pharmaceutical industry, Amazon
Numerous drugs such as Optivo, Yervoy, and Keytruda, have been approved by the FDA for treatment of cancers by boosting immunity though blocking immune inhibiting mechanisms.
Key Points:
- Numerous drugs such as Optivo, Yervoy, and Keytruda, have been approved by the FDA for treatment of cancers by boosting immunity though blocking immune inhibiting mechanisms.
- This class of drugs, called checkpoint inhibitors represent a 15.2 billion dollar a year market1.
- The current data and patent granted are representation of years of basic scientific investigation on the relationship between IDO and the immune system.
- Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases.